TBPH — Theravance Biopharma Share Price
0.000.00%
Last trade - 00:00- $454.86m
- $393.19m
- $57.42m
- 23
- 25
- 71
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 910.07 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.45 | ||
| Price to Tang. Book | 2.45 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.2 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -13.22% | ||
| Return on Equity | -22.88% | ||
| Operating Margin | -69.61% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 73.41 | 71.86 | 55.31 | 51.35 | 57.42 | 62.72 | 86.15 | -1% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.
Directors
- Rick Winningham CHM (61)
- Andrew Hindman CFO (48)
- Ann Brady CEX (54)
- Richard Graham SVP (47)
- Frank Pasqualone SVP (65)
- Kenneth Pitzer SVP (57)
- Philip Worboys SVP (51)
- William Young LED (76)
- Laurie Alsup IND (67)
- Eran Broshy IND (62)
- Burton Malkiel IND (88)
- Dean Mitchell IND (65)
- Susan Molineaux IND (67)
- Donal O'Connor IND (70)
- Deepika Pakianathan IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- July 1st, 2013
- Public Since
- May 16th, 2014
- No. of Shareholders
- 43
- No. of Employees
- 99
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 49,174,296
- Address
- UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, KY1-1104
- Web
- https://www.theravance.com/
- Phone
- +1 3456508086000
- Auditors
- Ernst & Young LLP
Upcoming Events for TBPH
Q4 2024 Theravance Biopharma Inc Earnings Release
Theravance Biopharma Inc Annual Shareholders Meeting
Q1 2025 Theravance Biopharma Inc Earnings Release
Similar to TBPH
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Theravance Biopharma share price?
As of Today at 22:41 UTC, shares in Theravance Biopharma are trading at $9.25. This share price information is delayed by 15 minutes.
How has the Theravance Biopharma share price performed this year?
Shares in Theravance Biopharma last closed at $9.25 and the price had moved by -11.74% over the past 365 days. In terms of relative price strength the Theravance Biopharma share price has underperformed the S&P500 Index by -32.4% over the past year.
What are the analyst and broker recommendations for Theravance Biopharma?
The overall consensus recommendation for Theravance Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Theravance Biopharma dividend yield?
Theravance Biopharma does not currently pay a dividend.
Does Theravance Biopharma pay a dividend?
Theravance Biopharma does not currently pay a dividend.
When does Theravance Biopharma next pay dividends?
Theravance Biopharma does not currently pay a dividend.
How do I buy Theravance Biopharma shares?
To buy shares in Theravance Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theravance Biopharma?
As of the previous close price of $9.25, shares in Theravance Biopharma had a market capitalisation of $454.86m.
Where are Theravance Biopharma shares listed?
Here are the trading details for Theravance Biopharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: TBPH
What kind of share is Theravance Biopharma?
Based on an overall assessment of its quality, value and momentum Theravance Biopharma is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theravance Biopharma share price forecast for 2024?
The analyst consensus target price for shares in Theravance Biopharma is $13.20. That is 42.7% above the last closing price of $9.25.
Analysts covering Theravance Biopharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.06 for the next financial year.
Find out moreWhat is the trend in the Theravance Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theravance Biopharma. Over the past six months, its share price has underperformed the S&P500 Index by -5.49%.
As of the last closing price of $9.25, shares in Theravance Biopharma were trading +4.69% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theravance Biopharma PE Ratio?
The Theravance Biopharma PE ratio based on its reported earnings over the past 12 months is 910.07. The shares last closed at $9.25.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theravance Biopharma?
Theravance Biopharma's management team is headed by:
- Rick Winningham - CHM
- Andrew Hindman - CFO
- Ann Brady - CEX
- Richard Graham - SVP
- Frank Pasqualone - SVP
- Kenneth Pitzer - SVP
- Philip Worboys - SVP
- William Young - LED
- Laurie Alsup - IND
- Eran Broshy - IND
- Burton Malkiel - IND
- Dean Mitchell - IND
- Susan Molineaux - IND
- Donal O'Connor - IND
- Deepika Pakianathan - IND